NuVision Biotherapies has announced the appointment of distributors for the whole of Ireland (North and South).
Following the market entry of its new wound care product Omnigen, a dry preserved amniotic membrane-derived therapy, into NHS and private healthcare ophthalmic market, NuVision Biotherapies is extending its reach by working with MED Surgical as its new distributor for the whole of Ireland.
MED Surgical has been delivering products into the Irish healthcare market for over 20 years.
Its representatives will be working with ophthalmic surgeons in order to facilitate access to Omnigen for the treatment of ocular surface disorders.
Dr Andrew Hopkinson, CEO of NuVision Biotherapies, said: “We are all very excited to work with MED Surgical to provide access to Omnigen for the people of Ireland.
"Our experience in England has been very positive, with over 30 hospitals, NHS and private already using Omnigen to help restore and retain patients' sight.
"Surgeons in England have found Omnigen to be convenient, easy to use and effective in the treatment of ocular surface disorders, and we look forward to offering the same opportunity for use to Irish ophthalmic surgeons”
